Vera Therapeutics is trading 4.9% up now at $35.35, supported by biotechnology strength and gains in major U.S. indexes.
- No new company-specific catalyst has been identified for August 25, 2026; XBI is up 2.06%.
- TRUTAKNA’s accelerated FDA approval and planned Q3 2026 efficacy data remain supportive background, but were announced earlier.
- Shares rose 4.48% to $33.72 on August 24, extending recent momentum; confidence is medium.